Table 1.
Prevalence of active smoking among patients with coronavirus disease 2019 (COVID-19) in major case series
| First author | Journal | Countries | Study sample size (n) | Patients’ age (years) | Active smokers among patients with COVID-19 (n) | Active smoking prevalence among patients with COVID-19 (%) | 2016 Country smoking age-adjusted prevalence (%)17 |
|---|---|---|---|---|---|---|---|
| Borba MGS9 | JAMA Netw Open | Brazil | 48 | 51 ± 13.9* | 4 | 8.3% | 14% |
| Guan W10 | N Engl J Med | China | 1085 | 47 (35–58)† | 137 | 12.6% | 25.2% |
| Guo T11 | JAMA Cardiol | China | 187 | 58.5 ± 14.66* | 18 | 9.6% | 25.2% |
| Huang C12 | Lancet | China | 41 | 49 (41–58)† | 3 | 7.3% | 25.2% |
| Mehra MR13 | N Engl J Med | USA, Canada, Spain, Italy, UK, Germany, France, Turkey, China, South Korea, Japan | 8910 | 49 ± 16* | 491 | 5.5% | na |
| Shen C14 | JAMA | China | 5 | 36–73‡ | 0 | 0% | 25.2% |
| Yang X15 | Lancet Respir Med | China | 52 | 59.7 ± 13.3* | 2 | 3.8% | 25.2% |
| Zhou F16 | Lancet | China | 191 | 56 (46–67)† | 11 | 5.8% | 25.2% |
na = not applicable; UK = United Kingdom; USA = United States of America.
*
Data presented as mean ± standard deviation.
†
Data presented as median (interquartile range).
‡
Data presented as range.